Oric Pharmaceuticals, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies targeting mechanisms of treatment resistance in cancer, with a pipeline focused on prostate cancer and other solid tumors.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Piscitelli DominicChief Financial Officer | Sell | $189K | 14,000at $13.53 | Oct 20, 2026 |
| Heyman Richard A.Insider | Sell | $45K | 3,500at $12.91 | Oct 1, 2026 |
| Heyman Richard A.Insider | Sell | $41K | 3,200at $12.91 | Oct 1, 2026 |
| Piscitelli DominicChief Financial Officer | Sell | $181K | 13,400at $13.53 | Sep 28, 2026 |
| Piscitelli DominicChief Financial Officer | Sell | $7K | 500at $13.51 | Sep 24, 2026 |
| Piscitelli DominicChief Financial Officer | Sell | $1K | 100at $13.50 | Sep 24, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ORIC activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.